One of the most important therapeutic classes according is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco.
One of the most important therapeutic classes according to Figure 2 is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco. "We estimate that the pharmacy spending in this class is going to increase dramatically."
According to Dr. Castle, in 2006 cancer spending grew nearly 38%, becoming the largest contributor to specialty drug trend. Almost 25% of all specialty drugs approved last year were for cancer. There are more than 500 new cancer drugs and indications for existing cancer drugs under development. These include the more targeted and personalized cancer therapies that are expected to comprise the majority of cancer drugs developed over the next five to seven years.
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen